Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Middle East Pharmaceutical Industries Co EV-to-FCF?
Middle East Pharmaceutical Industries CoSAU:4016 +0.92%22 EV-to-FCF is 65.09 as of Jul. 20, 2026, which is 4% below its 10-year median of 67.65. GuruFocus rates SAU:4016 with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 565 Drug Manufacturers companies, Middle East Pharmaceutical Industries Co ranks worse than 79.65% on this metric.
SAU:4016's EV-to-FCF is ranked worse than 79.65% of 565
companies
in the Drug Manufacturers industry
Industry Median: 20.96
vs SAU:4016: 64.99
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Middle East Pharmaceutical Industries Co (SAU:4016) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Middle East Pharmaceutical Industries Co's PE Ratio (TTM) for today is calculated as:
Middle East Pharmaceutical Industries Co's share price for today is ﷼60.55.
Middle East Pharmaceutical Industries Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ﷼2.983.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Middle East Pharmaceutical Industries Co EV-to-FCF Related Terms
Middle East Pharmaceutical Industries Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Middle East Pharmaceutical Industries Co EV-to-FCF Chart
Middle East Pharmaceutical Industries Co Annual Data
Trend
Dec23
Dec24
Dec25
EV-to-FCF
0.00
204.27
41.64
Middle East Pharmaceutical Industries Co Quarterly Data
For the Drug Manufacturers - Specialty & Generic subindustry, Middle East Pharmaceutical Industries Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Middle East Pharmaceutical Industries Co EV-to-FCF vs Drug Manufacturers Industry
Middle East Pharmaceutical Industries Co's current Enterprise Value is ﷼2,183.9 Mil.
Middle East Pharmaceutical Industries Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ﷼33.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Middle East Pharmaceutical Industries Co (SAU:4016) has a EV-to-FCF of 65.09 as of Jul. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Middle East Pharmaceutical Industries Co and its competitors. This is near median its historical median of 67.65. Over the past decade, Middle East Pharmaceutical Industries Co's EV-to-FCF has ranged from 30.75 to 742.50. According to the industry distribution chart, Middle East Pharmaceutical Industries Co ranks #450 out of 565 companies in the Drug Manufacturers industry, placing it in the top 79.6%.
Is Middle East Pharmaceutical Industries Co's EV-to-FCF too high?
Middle East Pharmaceutical Industries Co's current EV-to-FCF of 65.09 is near median its 10-year median of 67.65. Over the past 10 years, this metric has ranged from a low of 30.75 to a high of 742.50. The Drug Manufacturers industry median EV-to-FCF is 20.96. Middle East Pharmaceutical Industries Co's value of 65.09 is 210.5% above this industry median. Based on the distribution chart, Middle East Pharmaceutical Industries Co ranks #450 out of 565 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Middle East Pharmaceutical Industries Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Middle East Pharmaceutical Industries Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Middle East Pharmaceutical Industries Co ranks #450 out of 565 companies for EV-to-FCF. This places Middle East Pharmaceutical Industries Co in the lower half of its industry. The industry median EV-to-FCF is 20.96. Middle East Pharmaceutical Industries Co's value of 65.09 is 210.5% above this benchmark. Historically, Middle East Pharmaceutical Industries Co's own EV-to-FCF has ranged from 30.75 to 742.50 over the past decade. While the company's 10-year median is 67.65 vs. the industry median of 20.96, Middle East Pharmaceutical Industries Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.96, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Middle East Pharmaceutical Industries Co's current EV-to-FCF of 65.09 is 210.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Middle East Pharmaceutical Industries Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Middle East Pharmaceutical Industries Co's current EV-to-FCF is 65.09, which is near median its own 10-year median of 67.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Middle East Pharmaceutical Industries Co stock overvalued right now?
Middle East Pharmaceutical Industries Co (SAU:4016) has a current EV-to-FCF of 65.09. The current EV-to-FCF is 65.09, which is near median its 10-year median of 67.65 and 210.5% above the Drug Manufacturers industry median of 20.96. Middle East Pharmaceutical Industries Co's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Middle East Pharmaceutical Industries Co (SAU:4016), the current EV-to-FCF is 65.09 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Middle East Pharmaceutical Industries Co Business Description
Middle East Pharmaceutical Industries Co is a holding company engaged in manufacturing medicines, medicated and non-medicated creams and gels. The company operates in Private, Public, and Export segments. Geographically, it generates the majority of its revenue from Saudi Arabia.
22GF Score
Get the complete analysis for SAU:4016
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4016 has been successfully added to your 
